HIV/AIDS Clinical Trials in Philadelphia

Showing 281-300 of 621 trials

Doravirine, Rifapentine and Isoniazid Interaction

NCT03886701

Drug therapy for persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) co-infected with latent tuberculosis infection (LTBI) is complex. Anti-tuberculosis drugs used to treat LTBI often induce drug metabolizing enzymes that share the same metabolic pathway as antiretroviral drugs used for those living with HIV/AIDS. This study evaluates the drug-drug interaction (DDI) potential of an antiretroviral drug when co-administered with a common anti-tuberculosis regimen of drugs.

Latent TuberculosisHuman Immunodeficiency VirusRifamycins Causing Adverse Effects in Therapeutic Use+1 more

Walter K. Kraft11 participantsStarted Apr 2019

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 3< 1 mile

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

NCT00044577

A 48-week study to investigate the safety and effectiveness of a new compact formulation of two already FDA-approved anti-HIV drugs in subjects who have already been receiving treatment for their HIV infection.

Infection, Human Immunodeficiency Virus IHIV Infection

ViiV Healthcare166 participantsStarted Jul 2002

Los Angeles, California, United States • Oakland, California, United States • Fort Lauderdale, Florida, United States +73 more locations

Doravirine, Rifapentine and Isoniazid Interaction

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

HIV/AIDS Trials in Other Cities

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Tesamorelin Effects on Liver Fat and Histology in HIV

Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Other Conditions in Philadelphia